SCHEMBL1718504

SCHEMBL1718504

CC[C@H](NC(=O)c1c(C)n(-c2ccccc2)c(=O)c2c(N)cccc12)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 17/20 0.50
TACR2 P21452 6/20 0.50
PIK3CD O00329 3/20 0.46
PIK3CG P48736 3/20 0.46
PIK3R1 P27986 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
MAPK1 P28482 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
KMT2A Q03164 1/20 0.45
ATM Q13315 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1717253 0.90 TACR3 (0.47) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL1717820 0.88 TACR3 (0.51) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL1717894 0.88 PIK3CD (0.49) TACR3TACR2PIK3CDPIK3CGPIK3R1
SCHEMBL1716833 0.86 TACR3 (0.52) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL1717011 0.86 TACR3 (0.51) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL1717266 0.85 PPARG (0.44) TACR3TACR2PIK3CDPIK3CGPIK3R1
SCHEMBL1717651 0.85 TACR3 (0.43) TACR3TACR2PIK3CDPIK3CGCYP1A2
SCHEMBL1719222 0.85 TACR3 (0.41) TACR3TACR2PIK3CDPIK3CGPIK3R1
SCHEMBL1717145 0.85 TACR3 (0.43) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL1076846 0.84 PIK3CD (0.48) TACR3TACR2PIK3CDPIK3CGPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 TACR3 30/4885TACR2 31/4885PIK3CD 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.